FDA’s Surprise Vaping Pivot

The FDA’s Center for Tobacco Products issued guidance placing unauthorized e-cigarettes and nicotine pouches under “enforcement discretion” — a legal mechanism that allows the agency to decline to pursue products that haven’t been through its premarket review process.

Staff at the FDA’s Center for Tobacco Products say they were blindsided — many learned of the guidance the night before it was published and were not consulted during its drafting. STAT News reported that the new guidance effectively inverts the agency’s decade-long framework for protecting youth from nicotine products.

What Changed and What Didn’t

Previously, the FDA’s premarket authorization pathway required companies to demonstrate that their product was appropriate for the protection of public health before it could be sold. Under the new enforcement discretion framework, unauthorized products can remain on or enter the market while authorization decisions lag.

Nicotine pouches and flavored e-cigarettes are the primary product categories affected. The FDA had separately authorized mango- and blueberry-flavored products in the days before the guidance was published.

Why This Matters for People in Recovery

Nicotine use disorder co-occurs in an estimated 70–80% of people seeking treatment for other substance use disorders. An environment where flavored nicotine products face fewer regulatory barriers makes cessation harder for a population that already faces enormous challenges.

Learn about co-occurring nicotine treatment options alongside SUD recovery at Rize.